CMC Pharma Consulting BJ ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 4.9% 8.4% 10.2%  
Credit score (0-100)  0 0 43 28 23  
Credit rating  N/A N/A BBB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 3,524 5,176 4,950  
EBITDA  0.0 0.0 809 493 190  
EBIT  0.0 0.0 809 493 186  
Pre-tax profit (PTP)  0.0 0.0 788.7 474.0 172.7  
Net earnings  0.0 0.0 611.2 345.2 111.6  
Pre-tax profit without non-rec. items  0.0 0.0 789 474 173  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 41.0  
Shareholders equity total  0.0 0.0 651 396 208  
Interest-bearing liabilities  0.0 0.0 4.0 1.9 2.1  
Balance sheet total (assets)  0.0 0.0 1,137 799 614  

Net Debt  0.0 0.0 -286 -85.2 -24.5  
 
See the entire balance sheet

Volume 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 3,524 5,176 4,950  
Gross profit growth  0.0% 0.0% 0.0% 46.9% -4.4%  
Employees  0 0 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 1,137 799 614  
Balance sheet change%  0.0% 0.0% 0.0% -29.8% -23.1%  
Added value  0.0 0.0 808.9 492.8 190.2  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 36  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 1.0 2.0 3.0  

Profitability 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 23.0% 9.5% 3.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% 71.7% 53.8% 26.7%  
ROI %  0.0% 0.0% 124.5% 98.9% 62.1%  
ROE %  0.0% 0.0% 93.9% 65.9% 36.9%  

Solidity 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 0.0% 57.3% 49.6% 33.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% -35.3% -17.3% -12.9%  
Gearing %  0.0% 0.0% 0.6% 0.5% 1.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 1,357.4% 1,585.7% 804.0%  

Liquidity 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 2.3 2.0 1.4  
Current Ratio  0.0 0.0 2.3 2.0 1.4  
Cash and cash equivalent  0.0 0.0 289.5 87.1 26.6  

Capital use efficiency 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 651.2 396.4 166.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 809 493 190  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 809 493 190  
EBIT / employee  0 0 809 493 186  
Net earnings / employee  0 0 611 345 112